Elekta

Value proposition

"Nobody does adaptive like Elekta" — delivering adaptive radiotherapy as a new standard of care by combining precision, workflow, and evidence to respond to changes in patient anatomy throughout treatment. [1]

Where it wins

• Integrated MR-guided workflows: The Elekta Unity MR-Linac is the first high-field (1.5 tesla) system combining magnetic resonance imaging with radiation therapy, developed with UMC Utrecht and Philips. [4]
• Precision for complex indications: Specialized solutions for head and neck, breast, kidney, brain tumors, prostate, gynecological, and pancreatic cancers, preserving healthy tissue and function. [1]
• Proven clinical evidence: Over 50 years of advancing precision in cancer care, with evidence showing daily adaptation improves accuracy and long-term outcomes. [1]
• Comprehensive ecosystem: Combines hardware (linear accelerators, Gamma Knife, brachytherapy) with software (MOSAIQ, Monaco) for end-to-end oncology management. [4]

Credibility: Claims supported by Elekta’s official website [1] and Wikipedia’s product history [4].

Business model

• High-Value Medical Technology: Sells complex, regulated capital equipment and software to healthcare institutions, commanding high margins due to technological differentiation. [4]
• Installed Base Growth: Expands revenue through a growing installed base of ~7,500 devices, driving recurring service and software revenue. [4]
• Integrated Solutions: Combines hardware, software, and clinical expertise to create sticky, end-to-end workflows that are difficult for competitors to replicate. [1][4]
• Global Reach: Operates in over 40 countries with offices in key markets like Stockholm, Crawley, Veenendaal, Warsaw, Helsinki, Milan, Cairo, Istanbul, New Delhi, Seoul, Beijing, Shanghai, Hong Kong, Tokyo, Sydney, San Jose, Atlanta, Montreal, Mexico City, and São Paulo. [4]

Competitive landscape

• Varian Medical Systems: A major competitor in radiation therapy, but Elekta differentiates with its MR-guided Unity system and adaptive workflows. [4]
• Accuray: Competes in stereotactic radiosurgery, but Elekta’s Gamma Knife has a longer history and broader clinical evidence. [4]
• Siemens Healthineers: Offers MRI and radiation therapy solutions, but Elekta’s integrated MR-Linac is a unique differentiator. [4]
• Brainlab: Competes in treatment planning and navigation, but Elekta’s end-to-end ecosystem is more comprehensive. [4]

Differentiators: Elekta’s focus on adaptive radiotherapy and its integrated hardware-software ecosystem set it apart from competitors who may offer only partial solutions.

Market pains

• Anatomical Changes During Treatment: Tumors and surrounding tissues can change shape and position during radiotherapy, reducing treatment accuracy. [1]
• Complexity of Adaptive Workflows: Integrating imaging, planning, and treatment in real-time is technically challenging. [1]
• Need for Precision: Protecting healthy tissue and critical organs (e.g., heart, lungs, brain) requires high-precision targeting. [1]
• Workflow Efficiency: Oncology centers need streamlined workflows to handle increasing patient volumes. [1]
• Access to Advanced Technology: Many centers lack access to MR-guided or adaptive radiotherapy due to cost or complexity. [1]

Strategic implications

Elekta’s leadership in adaptive radiotherapy positions it to capture a growing share of the radiation therapy market as clinical evidence supports its efficacy. The main risk at scale is the high cost and complexity of MR-Linac systems, which may limit adoption in price-sensitive markets. The opportunity lies in expanding the installed base of adaptive systems and leveraging the existing ~7,500-device footprint for recurring revenue. The next signal that would change the thesis is a significant shift in reimbursement policies for adaptive radiotherapy or a breakthrough in competitor technology.

Improvement suggestions

Expand digital marketing efforts to highlight patient outcomes and clinical evidence, leveraging platforms like Pardot and Google Analytics more aggressively. Develop lower-cost adaptive radiotherapy solutions for emerging markets to address the access gap. Strengthen partnerships with academic institutions to generate more clinical data and build trust with healthcare providers. Enhance the service and support model to reduce downtime and improve customer satisfaction, particularly for the installed base of ~7,500 devices.